Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse   Donating Investigator David Ginsburg,   University of Michigan

Description
These mice carry the F5 Leiden mutation whereby the arginine at position 504 is replaced by a glutamine disrupting a cleavage site necessary for the inactivation of the factor V protein. Mice that are homozygous for this allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Clotting activity is indistinguishable from that of wildtype mice. Rarely, spontaneous vascular thrombo-embolic events are observed. Analysis of tissue fibrin content indicates increased deposition of fibrin in multiple tissues. When maintained on a mixed B6;129 genetic background, mice homozygous for this allele experience disseminated intravascular thrombosis resulting in increased fetal loss. This loss is not observed on a congenic C57BL/6J genetic background. This mutant mouse strain represents a model useful in research examining the disease aspects of the Leiden mutation and thrombosis in general.

Development
A targeting vector containing F5 exons 7-11, with a TK/neo cassette flanked by loxP sites located in intron 10 and a point mutation in exon 10 (mutation R504Q) was introduced into 129S2/SvPas-derived D3 embryonic stem (ES) cells. Correctly targeted ES cells were transiently transfected with supercoiled pMC-Cre plasmid DNA to remove the TK/neo cassette. ES cells bearing the R504Q mutation and bereft of the TK/Neo cassette were injected into C57BL/6J blastocysts. The resulting chimeric male animals were backcrossed to C57BL/6J females. Mutant mice were then backcrossed to C57BL/6J for twelve generations before being made homozygous.

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of F5

004078	B6.129S2-F5tm1Dgi/J
007244	B6;SJL-Tg(Alb-F5)2Dgi/J
007245	B6;SJL-Tg(Alb-F5)3Dgi/J
007243	B6;SJL-Tg(Cxcl4-F5)1Dgi/J

View Strains carrying other alleles of F5     (4 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI

- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Budd-Chiari Syndrome; BDCHS   (F5) Factor V Deficiency   (F5) Pregnancy Loss, Recurrent, Susceptibility to, 1; RPRGL1   (F5) Stroke, Ischemic   (F5) Thrombophilia Due to Activated Protein C Resistance; THPH2   (F5)

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

F5^tm2Dgi/F5⁺

        B6.129S2-F5^tm2Dgi

• homeostasis/metabolism phenotype
• abnormal blood coagulation
  • more resistant to anticoagulant activated protein C than controls, however F5 clotting activity is normal   (MGI Ref ID J:66260)
• • thrombosis
    • exhibit occasional spontaneous vascular thrombosis (e.g. necrosis of a digit)   (MGI Ref ID J:66260)

F5^tm2Dgi/F5^tm2Dgi

        B6.129S2-F5^tm2Dgi

• mortality/aging
• *normal* mortality/aging
  • do not observe postnatal lethality on the predominately C57BL/6J background like on the mixed 129 and C57BL/6J background, however crossing back to 129/SvJ or 129SvIm/J mice, results in about 50% postnatal loss   (MGI Ref ID J:66260)
• homeostasis/metabolism phenotype
• abnormal blood coagulation
  • chronic, low-grade thrombin generation leading to enhanced fibrin deposition in multiple tissues, however do not observe thrombosis   (MGI Ref ID J:66260)
• liver/biliary system phenotype
• liver fibrosis
  • occasional focal hepatic fibrosis is seen   (MGI Ref ID J:66260)

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

F5^tm2Dgi/F5^tm2Dgi

        involves: 129S2/SvPas * C57BL/6J

• mortality/aging
• *normal* mortality/aging
  • decreased number of expected pups at 3 weeks of age but not at 1-2 days before birth, however do not observe lethality on a predominately C57BL/6J background   (MGI Ref ID J:66260)
• homeostasis/metabolism phenotype
• abnormal blood coagulation
  • more resistant to anticoagulant activated protein C than controls or heterozygotes, however F5 clotting activity is normal   (MGI Ref ID J:66260)
• • thrombosis
    • widespread thrombosis affecting multiple organs, including brain, liver, heart, pancreas, and spleen, in all newborns   (MGI Ref ID J:66260)
• behavior/neurological phenotype
• lethargy
  • subset of mice appear lethargic at birth   (MGI Ref ID J:66260)
• integument phenotype
• pallor
  • subset of mice appear pale at birth   (MGI Ref ID J:66260)

F5^tm2Dgi/F5^tm2Dgi

        involves: 129S2/SvPas * C57BL/6

• mortality/aging
• partial neonatal lethality
  • around 20% of homozygotes die in neonatal period   (MGI Ref ID J:62716)
• homeostasis/metabolism phenotype
• thrombosis
  • homozygotes that die show microvascular thrombosis in neonatal period   (MGI Ref ID J:62716)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

F5^tm2Dgi related

Hematological Research
Clotting Defects

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		F5tm2Dgi
Allele Name		targeted mutation 2, David Ginsburg
Allele Type		Targeted (knock-in)
Common Name(s)		FVLeiden; FVLq; FvQ; FvL; FvR504Q;
Mutation Made By		Jisong Cui,   University of Michigan
Strain of Origin		129S2/SvPas
ES Cell Line Name		D3
ES Cell Line Strain		129S2/SvPas
Promoter		F5, coagulation factor V, mouse, laboratory
Molecular Note		A point mutation was introduced which altered the codon corresponding to amino acid 504 from an arginine to a glutamine. A loxP flanked neomycin cassette in intron 10 was removed by Cre-mediated recombination in ES cells prior to blastocyst injection. [MGI Ref ID J:66260]

Genotyping

Genotyping Information

Genotyping Protocols

F5^tm2Dgi, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Cui J; Eitzman DT; Westrick RJ; Christie PD; Xu ZJ; Yang AY; Purkayastha AA; Yang TL; Metz AL; Gallagher KP; Tyson JA; Rosenberg RD; Ginsburg D. 2000. Spontaneous thrombosis in mice carrying the factor V leiden mutation Blood 96(13):4222-6. [PubMed: 11110695]  [MGI Ref ID J:66260]

Additional References

Yin ZF; Huang ZF; Cui J; Fiehler R; Lasky N; Ginsburg D; Broze GJ Jr. 2000. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 97(12):6734-8. [PubMed: 10829076]  [MGI Ref ID J:62716]

F5^tm2Dgi related

An J; Waitara MS; Bordas M; Arumugam V; Hoffmann RG; Petrich BG; Sinha U; North PE; Sood R. 2013. Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model. Blood 121(11):2127-34. [PubMed: 23325830]  [MGI Ref ID J:195883]

Eitzman DT; Westrick RJ; Shen Y; Bodary PF; Gu S; Manning SL; Dobies SL; Ginsburg D. 2005. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 111(14):1822-5. [PubMed: 15809370]  [MGI Ref ID J:109686]

Kisucka J; Chauhan AK; Zhao BQ; Patten IS; Yesilaltay A; Krieger M; Wagner DD. 2009. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 113(23):6015-22. [PubMed: 19349621]  [MGI Ref ID J:149496]

Parker AC; Mundada LV; Schmaier AH; Fay WP. 2004. Factor VLeiden inhibits fibrinolysis in vivo. Circulation 110(23):3594-8. [PubMed: 15569834]  [MGI Ref ID J:103734]

Seehaus S; Shahzad K; Kashif M; Vinnikov IA; Schiller M; Wang H; Madhusudhan T; Eckstein V; Bierhaus A; Bea F; Blessing E; Weiler H; Frommhold D; Nawroth PP; Isermann B. 2009. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation 120(9):774-84. [PubMed: 19687358]  [MGI Ref ID J:167110]

Shen Y; Bodary PF; Vargas FB; Homeister JW; Gordon D; Ostenso KA; Shayman JA; Eitzman DT. 2006. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 37(4):1106-8. [PubMed: 16514103]  [MGI Ref ID J:135765]

Sood R; Zogg M; Westrick RJ; Guo YH; Kerschen EJ; Girardi G; Salmon JE; Coughlin SR; Weiler H. 2007. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med 204(5):1049-56. [PubMed: 17438064]  [MGI Ref ID J:125742]

Sun H; Wang X; Degen JL; Ginsburg D. 2009. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 113(6):1358-64. [PubMed: 19056689]  [MGI Ref ID J:145540]

Wang H; Madhusudhan T; He T; Hummel B; Schmidt S; Vinnikov IA; Shahzad K; Kashif M; Muller-Krebs S; Schwenger V; Bierhaus A; Rudofsky G; Nawroth PP; Isermann B. 2011. Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood 117(19):5231-42. [PubMed: 21389321]  [MGI Ref ID J:173276]

Yin ZF; Huang ZF; Cui J; Fiehler R; Lasky N; Ginsburg D; Broze GJ Jr. 2000. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 97(12):6734-8. [PubMed: 10829076]  [MGI Ref ID J:62716]

Zhang J; Tu Y; Lu L; Lasky N; Broze GJ Jr. 2008. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 111(10):4973-8. [PubMed: 18344422]  [MGI Ref ID J:136102]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & Husbandry	This strain originated on a B6;129P background and has been backcrossed to C57BL/6J for twelve generations before being made homozygous.
Diet Information	LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

General Supply Notes

• Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.